PATENT CLAIM ANALYSIS

Application Number: 15864994
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "245000"]

Abstract:
Provided are compounds useful for treating cancer and methods of treating cancer, for example an advanced solid tumor, such as a glioma, or angioimmunoblastic T-cell lymphoma (AITL).

Claim (Index 27):
The method of  claim 25 , wherein the crystalline form of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl] amino}-1,3,5-triazin-2-yl)amino]propan-2-ol is administered orally.

Metadata:
- Claim Count in Document: 70.0
- Percentile: 86.0
- Lexical Diversity: 1.17857
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14909451', '15649551', '15612984', '14868283', '15548737']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8530298823548326
- 35 USC 102 Novelty (BERT): 0.5807851987727062
- Combined Prediction Score: 0.82580541399662
- Mean Citation Score: 489.79634
- Max Citation Score: 507.67773
- Similarity Product: 398.39385732109673

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test